106 related articles for article (PubMed ID: 23032906)
1. Associations between TFPI-2 methylation and poor prognosis in glioblastomas.
Vaitkienė P; Skiriutė D; Skauminas K; Tamašauskas A
Medicina (Kaunas); 2012; 48(7):345-9. PubMed ID: 23032906
[TBL] [Abstract][Full Text] [Related]
2. GATA4 and DcR1 methylation in glioblastomas.
Vaitkienė P; Skiriutė D; Skauminas K; Tamašauskas A
Diagn Pathol; 2013 Jan; 8():7. PubMed ID: 23320456
[TBL] [Abstract][Full Text] [Related]
3. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.
Konduri SD; Srivenugopal KS; Yanamandra N; Dinh DH; Olivero WC; Gujrati M; Foster DC; Kisiel W; Ali-Osman F; Kondraganti S; Lakka SS; Rao JS
Oncogene; 2003 Jul; 22(29):4509-16. PubMed ID: 12881707
[TBL] [Abstract][Full Text] [Related]
4. Promoter methylation of AREG, HOXA11, hMLH1, NDRG2, NPTX2 and Tes genes in glioblastoma.
Skiriutė D; Vaitkienė P; Ašmonienė V; Steponaitis G; Deltuva VP; Tamašauskas A
J Neurooncol; 2013 Jul; 113(3):441-9. PubMed ID: 23624749
[TBL] [Abstract][Full Text] [Related]
5. TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma.
Wang S; Xiao X; Zhou X; Huang T; Du C; Yu N; Mo Y; Lin L; Zhang J; Ma N; Murata M; Huang G; Zhang Z
BMC Cancer; 2010 Nov; 10():617. PubMed ID: 21062455
[TBL] [Abstract][Full Text] [Related]
6. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
7. Promoter of TFPI-2 is hypermethylated in Chinese pediatric acute myeloid leukemia.
Jian P; Yan WS; Chao SL; Liang P; Zhen L; Ling QB; Hong LY; Ping LY; Jian W; Fang JM; Ling L; Dong WX; Ming ZX; Jian N
J Pediatr Hematol Oncol; 2012 Jan; 34(1):43-6. PubMed ID: 22052167
[TBL] [Abstract][Full Text] [Related]
8. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
[TBL] [Abstract][Full Text] [Related]
9. TFPI-2 methylation predicts poor prognosis in non-small cell lung cancer.
Wu D; Xiong L; Wu S; Jiang M; Lian G; Wang M
Lung Cancer; 2012 Apr; 76(1):106-11. PubMed ID: 21983100
[TBL] [Abstract][Full Text] [Related]
10. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.
Reifenberger G; Hentschel B; Felsberg J; Schackert G; Simon M; Schnell O; Westphal M; Wick W; Pietsch T; Loeffler M; Weller M;
Int J Cancer; 2012 Sep; 131(6):1342-50. PubMed ID: 22139906
[TBL] [Abstract][Full Text] [Related]
11. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
[TBL] [Abstract][Full Text] [Related]
12. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation and silencing of tissue factor pathway inhibitor-2 in oral squamous cell carcinoma.
Lai YH; He RY; Chou JL; Chan MW; Li YF; Tai CK
J Transl Med; 2014 Sep; 12():237. PubMed ID: 25179542
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power.
Franceschi E; Tosoni A; Minichillo S; Depenni R; Paccapelo A; Bartolini S; Michiara M; Pavesi G; Urbini B; Crisi G; Cavallo MA; Tosatto L; Dazzi C; Biasini C; Pasini G; Balestrini D; Zanelli F; Ramponi V; Fioravanti A; Giombelli E; De Biase D; Baruzzi A; Brandes AA;
World Neurosurg; 2018 Apr; 112():e342-e347. PubMed ID: 29337169
[TBL] [Abstract][Full Text] [Related]
15. A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma.
Wang W; Zhang L; Wang Z; Yang F; Wang H; Liang T; Wu F; Lan Q; Wang J; Zhao J
Oncotarget; 2016 Oct; 7(43):69991-69999. PubMed ID: 27588397
[TBL] [Abstract][Full Text] [Related]
16. Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma.
Brigliadori G; Foca F; Dall'Agata M; Rengucci C; Melegari E; Cerasoli S; Amadori D; Calistri D; Faedi M
J Neurooncol; 2016 Jun; 128(2):333-9. PubMed ID: 27029617
[TBL] [Abstract][Full Text] [Related]
17. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
[TBL] [Abstract][Full Text] [Related]
18. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
19. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
20. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
